

cc - Dr. Tabor

May 21, 1964

Dr. William R. Tabor
A. H. Robins Company, Inc.
1407 Cummings Drive
Richmond 20, Virginia

Dear Dr. Tabor:

Enclosed are protocols on nineteen patients treated with butaperazine from August, 1963 to date, and summaries of the data. This information has been put together at your request, and reports the first phase of a two-part study of the influence of butaperazine in the treatment of patients classified as "therapeutic resistant" psychotics.

Following the letter of Dr. Seaholm of May 14, 1963, it is our estimate that the direct costs for this study are as follows:

Personnel time	\$2,500
Laboratory studies (including EEG)	1,500
Supplies	-
Travel	-
Total	<u>\$4,000</u>

We would like to continue the study and the next phase will encompass an expansion of this group to include twenty-one more patients and ten subjects to be observed in the same environment, using trifluoperazine or chlorpromazine. The exact protocol for this part of the study and the study grant request are enclosed.

In addition, Dr. Keskiner has indicated that our present supply of butaperazine will be exhausted within a month, and we would like additional supplies as follows:

Liquid	300 pints
Capsules	2,000/10 mg.

In addition, we would appreciate a supply of ampoules for parenteral use, and will need 200 ampoules of 10 mg. each.

Sincerely yours,

Max Fink, M. D.
Director

MF/jb
Enc.